NGL Fine-Chem Limited
₹2,790.00▼ -16.30 (-0.58%)
NGLFINE·NSE·Healthcare
Market Cap
1735.84 Cr
PE Ratio
41.41
Volume
3,031
Day High - Low
2857.20 - 2772.00
52W High-Low
3602.00 - 1271.00
₹2,790.00▼ -16.30 (-0.58%)
Market Cap1735.84 Cr
PE Ratio41.41
Volume3,031
Day High - Low2857.20 - 2772.00
52W High-Low3602.00 - 1271.00
NGL Fine-Chem Limited (NGLFINE): company summary
The company's business is improving, with annual revenue rising 39.5% and net profit surging 167.4%.
NGL Fine-Chem Limited (NGLFINE) is a micro-cap Healthcare company valued at ₹1,736 crore operating in Pharmaceuticals on the NSE and BSE.
- Recent price move
- NGL Fine-Chem Limited last traded at ₹2,790, modestly down 0.58% on the day.
- Recent developments
- On 2026-08-18, the company announced a dividend of ₹1.75 per share, with the ex-date set for that day. The latest quarter ended on 2026-06-30, showing strong growth in both revenue and net profit compared to the same quarter a year earlier. Promoter holding decreased by 0.25 percentage points to 72.49% as of 2026-06-30.
- Financial performance
- The company's business is improving, with annual revenue rising 39.5% and net profit surging 167.4%. The latest quarter saw revenue and net profit both grow significantly, with revenue up 37.8% and net profit jumping 130.0% compared to the same quarter a year earlier. The net profit margin has widened to 9.6% from 5.0% a year ago, while return on capital employed stands at 15.5%.
- Valuation multiples
- The stock trades at 41.4 times earnings, a premium to the Healthcare median of 32.0, 5.49 times book value. It yields 0.1%.
- Things to watch
- The company's return on equity is 0.0%, which is a concern for profitability relative to shareholders' equity. The stock is 18.8% below its 52-week high, indicating a significant drop from recent peak levels. Promoter holding has slightly declined, which may signal a shift in ownership or confidence.
- Where it stands
- The company has shown strong growth in both revenue and net profit over the past year and quarter, with a notable widening of the net profit margin. The stock is currently 18.8% below its 52-week high, and promoter holding has decreased slightly. The return on equity remains at 0.0%, which is a key point to note.
Summarised by DocStoX's model on 2026-10-04 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.
DocStoX Score
4.3/10
Weak
Fair Value
Sign in to see
ROE
0.00%
Weak
P/E
41.41x
Expensive
Debt / Equity
0.33
Moderate
Industry
Healthcare
Pharmaceuticals
Overall View
Mixed
Price performance
Day₹2772
₹2857
52W₹1271
₹3602
DocStoX take
Supported by risk (7.6) and momentum (7.2), but held back by valuation (0.5). Risk looks strong at 7.6, but that is offset by valuation at 0.5 and growth at 2.4. We are calling it Mixed rather than resolving the conflict for you.
DocStoX score
Low confidence4.3
/10
Weak
Quality
Modest
ROE 0.0%
Valuation
Expensive
P/E 41.4×
Growth
Flat
Revenue +14.2% 5Y CAGR
Risk
Low risk
D/E 0.33
Momentum
Firm
65% of 52-week range
At a glance
Market Cap
₹1,736 Cr
52W High / Low
₹3602 / ₹1271
Dividend Yield
0.06%
Promoter Holding
72.49%
EPS (TTM)
₹67.38
Book Value
₹532.91
Key highlights
- Profitable in all of the last 5 years
- Profit shrinking 3% a year
- Valuation is weak (0.5/10)
1 Positive3 Watchouts
Growth
Financials
Technicals
Peers
News
Forecasts
About the company
More data
Filings, corporate actions and ownership detail — opened on demand.
More Healthcare stocks · Pharmaceuticals
Explore NGL Fine-Chem Limited’s valuation
Free deep-dive tools · no sign-up
Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.
NGL Fine-Chem Limited peers in Healthcare
Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.
Sun Pharmaceutical Industries LimitedDivi's Laboratories LimitedTorrent Pharmaceuticals LimitedApollo Hospitals Enterprise LimitedZydus Lifesciences LimitedLaurus Labs LimitedCipla LimitedDr. Reddy's Laboratories LimitedAurobindo Pharma LimitedMankind Pharma LimitedLupin LimitedManipal Health Enterprises Limited
Compare NGL Fine-Chem Limited with peers
NGL Fine-Chem Limited vs Sun Pharmaceutical Industries LimitedNGL Fine-Chem Limited vs Divi's Laboratories LimitedNGL Fine-Chem Limited vs Torrent Pharmaceuticals LimitedNGL Fine-Chem Limited vs Apollo Hospitals Enterprise LimitedNGL Fine-Chem Limited vs Zydus Lifesciences LimitedNGL Fine-Chem Limited vs Laurus Labs Limited
Related tools & concepts
Value NGL Fine-Chem Limited with the ratios and calculators DocStoX uses in its analysis.
P/E RatioPrice to earningsReturn on Equity (ROE)ProfitabilityROCECapital efficiencyDebt to EquityLeverageP/B RatioPrice to bookNet Profit MarginBottom-line efficiencyDCF / Intrinsic ValueEstimate fair valueCAGR CalculatorAnnualised returnDividend YieldIncome on pricePosition SizeRisk-based sizingBrokerage CalculatorCharges on a tradeSIP CalculatorSystematic investing